| October 9, 2019 |
Webinar: Establishing Qualified Bioassays for Checkpoint Receptors to Implement in QC Lot Release: Case Studies on PD-1 and SIRPα - 60 min.
|
Login to view
|
Login to view
|
| December 6, 2017 |
Webinar: Application of β-Arrestin Assays to the Orphan GPCR World - 30 min.
|
Login to view
|
Login to view
|
| November 29, 2017 |
Webinar: Implementing ADCC assays in QC: When donor variability isn’t an option - 55 min.
|
Login to view
|
Login to view
|
| November 1, 2017 |
Webinar: How to Accelerate Your Biotherapeutic Development with Cell-Based Assay Services - 40 min.
What will be covered?
- How PathHunter services save development time compared to in-house assays
- Screening and profiling biologics with highly specific and sensitive assays that produce robust and reproducible results
- Example data from marketed drugs, like Pembrolizumab and Nivolumab, using these cell-based assays
|
Login to view
|
Login to view
|
| September 20, 2017 |
Webinar: Create Your Own Cell-Based Assays to Study Receptor Tyrosine Kinase Function - 30 min.
What will be covered?
- RTK biology and drug discovery importance
- Tools needed to create your own RTK cell lines and assays
- Experimental design and workflows
- Applications of RTK and related cell-based assays
|
Login to view
|
Login to view
|
| June 27, 2017 |
Webinar: Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells - 55 min.
What will be covered?
- Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
- Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
- Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells
|
Login to view
|
Login to view
|
| May 18, 2017 |
Create Your Own Cellular Target Engagement Assay - 30 min.
What will be covered?
- Overview of compound-target engagement
- Tools and workflow to create your own cell-based target engagement assay
- Applications of InCELL Pulse assays
|
Login to view
|
Login to view
|
| April 19, 2017 |
Webinar: Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing - 40 min.
What will be covered?
- Using phenotypic profiling to characterize clinically successful drugs for a given indication
- Combining target-based and phenotypic data to prioritize drugs for repurposing
- Understanding how multi-targeted kinases can be pivoted towards new indications
|
Login to view
|
Login to view
|
| April 5, 2017 |
Webinar: From Chemistry to Clinic: Discovery of Biased Apelin Receptor Agonists and Action in the Cardiovascular System - 55 min.
What will be covered?
- Role of GPCRs in human cardiovascular system
- Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
- Identifying biased agonists using pharmacologically-relevant functional cell based assays
- Validating assays and minimizing inter-assay variation
|
Login to view
|
Login to view
|
| March 29, 2017 |
Webinar: Creating Cellular Target Engagement Assays for Diverse Kinases Using InCELL Pulse™ - 30 min.
What will be covered?
- Overview of compound-target engagement and InCELL Pulse platform
- Kinase drug discovery importance
- Tools and workflow needed to create your own target engagement assay
- Validation data showing several examples of diverse kinases
|
Login to view
|
Login to view
|
| March 10, 2017 |
免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.
What will be covered?
- 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
- PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
- 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系
|
Login to view
|
Login to view
|
| March 9, 2017 |
Webinar: Mu Opioid Receptor Splicing and Signaling: Another Dimension of GPCR Function - 55 min.
What will be covered?
- Overview of the mu opioid receptor signaling
- GPCR splicing, using OPRM1 as an example
- Region and cell specific splicing
- Functional consequences of 5’ splicing
- Functional consequences of 3’ splicing
|
Login to view
|
Login to view
|
| November 30, 2016 |
Webinar: Create Your Own InCELL Pulse™ Cellular Compound-Target Engagement Assay - 60 min.
What will be covered?
- Overview of compound-target engagement
- Tools needed to create your own target engagement assay
- Experimental design and workflow
- Applications of InCELL Pulse assays
|
Login to view
|
Login to view
|
| November 9, 2016 |
Webinar: Duplexed Screening of GPCRs to Measure Calcium and β-Arrestin - 60 min.
What will be covered?
- Screening approaches for GPCR drug discovery
- Creating a duplexed assay to monitor calcium and β-arrestin in a single well
- Determine potential bias for various drugs and define potency ranking
|
Login to view
|
Login to view
|
| October 26, 2016 |
Webinar: Target to Phenotype: Tools to Accelerate Your Immuno-Oncology Drug Pipeline - 60 min.
What will be covered?
- Challenges in immuno-oncology drug development
- Tools to expedite and simplify any immuno-oncology drug development pipeline
|
Login to view
|
Login to view
|
| September 30, 2016 |
Webinar: Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models - 60 min.
What will be covered?
- Overview of the BioMAP® immuno-oncology/oncology systems
- Information BioMAP iOnc studies provide
- Host stromal/vascular - tumor microenvironment biology
- Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds
|
Login to view
|
Login to view
|
| August 10, 2016 |
Webinar: New Tricks for Old Drugs: An Unbiased Phenotypic Approach to Drug Repurposing - 40 min.
What will be covered?
- Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
- Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
- Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications
|
Login to view
|
Login to view
|
| May 25, 2016 |
Webinar: A Phenotypic Platform for Characterization of Drug Safety Mechanisms in Human Primary Cell Disease Models - 40 min.
What will be covered?
- How to maximize knowledge of your compounds using the BioMAP® Diversity PLUS™ panel of human primary cells systems
- How to understand mechanism classification analysis and toxicity signatures
- A case study on discovery of a mechanism-based novel signature for skin irritation
|
Login to view
|
Login to view
|
| May 19, 2016 |
Webinar: Ready-to-use Potency Assays for Anti-VEGF Drugs Like Bevacizumab, Ranibizumab & Aflibercept - 60 min.
What will be covered?
- Creation of cell-based bioassays for potency and stability testing
- Application, development and validation of assays with drug molecule
- Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
- Qualified assays for > 30 biosimilars
|
Login to view
|
Login to view
|